Share on Facebook
Share on Twitter
Share on LinkedIn

(Reuters Health) – Many high-risk therapeutic devices get Food and Drug Administration (FDA) approval with only one study proving their safety and efficacy before going to market.

Studies of how the devices work once they are on the market are also few and far between, according to a new study that looked at all 28 high-risk devices approved in 2010 and 2011 by the FDA Premarket Approval pathway.

Read More